Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$23.8m

Jasper Therapeutics Management

Management criteria checks 0/4

Jasper Therapeutics' CEO is Jeet Mahal, appointed in Jan 2026, has a tenure of less than a year. total yearly compensation is $1.29M, comprised of 38.6% salary and 61.4% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth $17.94K. The average tenure of the management team and the board of directors is 0.6 years and 3 years respectively.

Key information

Jeet Mahal

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage38.62%
CEO tenureless than a year
CEO ownership0.08%
Management average tenureless than a year
Board average tenure3yrs

Recent management updates

Recent updates

Analysis Article • Jan 08

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 30

Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 04

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 18

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Summary Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved markets. Despite positive preliminary clinical results, Jasper faces financial risks, needing additional funds by Q3 2025, which may lead to shareholder dilution. Analysts rate JSPR as a strong buy with a $69.5 target, but caution is advised due to the speculative nature and financial instability. Investors should monitor upcoming clinical trial results for Briquilimab in January 2025, which could significantly impact Jasper's stock performance and future prospects. Read the full article on Seeking Alpha
Analysis Article • Aug 30

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 23

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 31

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 02

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Jeet Mahal's remuneration changed compared to Jasper Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$32m

Mar 31 2026n/an/a

-US$56m

Dec 31 2025US$1mUS$498k

-US$76m

Sep 30 2025n/an/a

-US$91m

Jun 30 2025n/an/a

-US$91m

Mar 31 2025n/an/a

-US$79m

Dec 31 2024US$1mUS$481k

-US$71m

Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$62m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$1mUS$462k

-US$64m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$1mUS$418k

-US$38m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$461kUS$355k

-US$31m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$40m

Dec 31 2020US$720kUS$330k

-US$32m

Compensation vs Market: Jeet's total compensation ($USD1.29M) is above average for companies of similar size in the US market ($USD650.37K).

Compensation vs Earnings: Jeet's compensation has increased whilst the company is unprofitable.

CEO

Jeet Mahal (54 yo)

less than a year
Tenure
US$1,289,599
Compensation

Mr. Jeetinder Singh Mahal, also Known as Jeet, M.B.A., M.E., M.B., serves as President, CEO & Director from January 5, 2026 and served as Chief Financial of Jasper Therapeutics, Inc. since December 2019 un...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Wiggans
Executive Chairman2.8yrsUS$109.77k0.14%
$ 33.0k
Jeetinder Mahal
Presidentless than a yearUS$1.29m0.075%
$ 17.9k
Judith Shizuru
Co-Founderno dataUS$86.07k0.47%
$ 112.6k
Herbert Cross
CFO & Corporate Secretary2.9yrsUS$1.28m0%
$ 0
Matthew Ros
Chief Operating Officerless than a yearno datano data
Alex Gray
Head of Investor Relationsno datano datano data
Matthew Ford
Senior Vice President of Human Resources3.6yrsno datano data
Luca Di Noto
Senior Vice President of Technical Operationsno datano datano data
0.6yrs
Average Tenure
59yo
Average Age

Experienced Management: JSPR's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Wiggans
Executive Chairman2.8yrsUS$109.77k0.14%
$ 33.0k
Jeetinder Mahal
Presidentless than a yearUS$1.29m0.075%
$ 17.9k
Judith Shizuru
Co-Founder8.4yrsUS$86.07k0.47%
$ 112.6k
Kurt von Emster
Independent Director6.8yrsUS$106.57k0.0064%
$ 1.5k
Daniel Adelman
Member of Scientific Advisory Board & Senior Clinical Advisor3.2yrsno datano data
Arthur Weiss
Member of Scientific Advisory Boardno datano datano data
Frederick Appelbaum
Member of Scientific Advisory Boardno datano datano data
Jeffrey Ravetch
Member of Scientific Advisory Boardno datano datano data
Stephen Galli
Member of Scientific Advisory Board3.3yrsno datano data
Svetlana Lucas
Independent Director2.2yrsUS$79.77k0.060%
$ 14.3k
Harry Malech
Member of Scientific Advisory Boardno datano datano data
Joshua Boyce
Member of Scientific Advisory Board1.6yrsno datano data
3.0yrs
Average Tenure
69.5yo
Average Age

Experienced Board: JSPR's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/24 18:47
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jasper Therapeutics, Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangCapital One Securities, Inc.
Silvan TuerkcanCitizens JMP Securities, LLC
Gavin Clark-GartnerEvercore ISI